Imtiaz Alam, MD

Clinical Associate Professor

19962017
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Bio

In addition to her role as Clinical Associate Professor in the Department of Internal Medicine at Dell Medical School, she is the medical director for the medical provider for HCV training program. Recently, Dr. Alam was the principal investigator for the Gilead Sciences FOCUS Grant to implement and expand Hepatitis C screenings for individuals in Substance Abuse Treatment Centers.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Ribavirin Medicine & Life Sciences
Chronic Hepatitis C Medicine & Life Sciences
Hepacivirus Medicine & Life Sciences
etoricoxib Medicine & Life Sciences
interferon alfa-2b Medicine & Life Sciences
Cholestasis Medicine & Life Sciences
Hepatic Insufficiency Medicine & Life Sciences
Intrahepatic Cholestasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1996 2017

5 Citations

Real-world effectiveness of Simeprevir-containing regimens among patients with chronic hepatitis C virus: The SONET study

Alam, I., Brown, K., Donovan, C., Forlenza, J., Lauwers, K., Mah'moud, M. A., Manch, R., Mohanty, S. R., Prabhakar, A., Reindollar, R., DeMasi, R., Slim, J., Tandon, N., Villadiego, S. & Naggie, S., Jan 1 2017, In : Open Forum Infectious Diseases. 4, 1

Research output: Contribution to journalArticle

Chronic Hepatitis C
Hepacivirus
Fibrosis
Ribavirin
Genotype
101 Citations

Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection

HCV-TARGET Study Group, Feb 1 2016, In : Gastroenterology. 150, 2, p. 419-429 11 p.

Research output: Contribution to journalArticle

Ribavirin
Hepacivirus
Genotype
Infection
Therapeutics
62 Citations

Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET

Gordon, S. C., Muir, A. J., Lim, J. K., Pearlman, B., Argo, C. K., Ramani, A., Maliakkal, B., Alam, I., Stewart, T. G., Vainorius, M., Peter, J., Nelson, D. R., Fried, M. W. & Reddy, K. R., Jan 1 2015, In : Journal of Hepatology. 62, 2, p. 286-293 8 p.

Research output: Contribution to journalArticle

Chronic Hepatitis C
Safety
Ribavirin
Therapeutics
Protease Inhibitors
11 Citations

Enhanced adherence to HCV therapy with higher dose ribavirin formulation: Final analyses from the ADHERE registry

Alam, I., Stainbrook, T., Cecil, B. & Kistler, K. D., Aug 1 2010, In : Alimentary Pharmacology and Therapeutics. 32, 4, p. 535-542 8 p.

Research output: Contribution to journalArticle

Ribavirin
Hepatitis C
Hepacivirus
Registries
Therapeutics
41 Citations

Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2 a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C

Perrillo, R., Rothstein, K. D., Rubin, R., Alam, I., Imperial, J., Harb, G., Hu, S. & Klaskala, W., Mar 1 2004, In : Journal of Viral Hepatitis. 11, 2, p. 157-165 9 p.

Research output: Contribution to journalArticle

interferon alfa-2b
Ribavirin
Chronic Hepatitis C
Quality of Life
Therapeutics